Key result
In rat models of hypertension and type 2 diabetes, CGS 35601 effectively lowered blood pressure and modulated plasma concentrations of vasoactive peptidic mediators.
Why the study?
Does CGS 35601 lower blood pressure and modulate vasoactive mediators in rat models of hypertension and diabetes?
Population
Healthy normotensive, hypertensive (SHR and DSS) and type 2 diabetic (ZDF-fatty) rats
Design
Preclinical
Follow-up
30 days
Authors
Loading...
Hypothesis-generating in rodent models; human trials required before any clinical consideration.
Does CGS 35601 lower blood pressure and modulate vasoactive mediators in rat models of hypertension and diabetes?
CGS 35601, a novel triple vasopeptidase inhibitor, effectively lowers blood pressure in preclinical models, suggesting potential as a new class of antihypertensive therapy.
Battistini et al. (2006) studied Hypertension and type 2 diabetes (animal models). CGS 35601 was evaluated on Blood pressure and plasma concentrations of vasoactive peptidic mediators. In rat models of hypertension and type 2 diabetes, CGS 35601 effectively lowered blood pressure and modulated plasma concentrations of vasoactive peptidic mediators.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: